Archer Materials Limited (ARRXF) Fair Value & Analysis
Technology · US · Market cap $68.8M
Archer Materials Limited
ARRXF · US
Fair value as of: Jul 14, 2026
From 1 valuation models · updated 9 days ago
Fair value updated Jul 14, 2026, revised from $0.1400 to $0.0600 (−57.1%) since Jun 24, 2026. Share price −43.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.1398 – $0.3217 · fair‑value band $0.0400 – $0.0800 · the $0.1530 price screens above the $0.0600 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Archer Materials Limited (ARRXF) currently trades at $0.1530, while our model-based Fair Value estimate is $0.0600, implying the stock looks roughly 60.8% overvalued today. We read business quality at 37/100 (below-average quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $2.2M. Revenue grew 13.8% year over year. It earns a return on equity of -33.6%. The balance sheet holds a net cash position of $2.6M. Fundamentals as of Jul 14, 2026
Our scenario range runs from $0.0400 (bear case) to $0.0800 (bull case); at $0.1530, the current price sits above that range. The share trades about 57% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at -74% fair-value upside, at -61%, ARRXF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Archer Materials Limited, a technology company, engages in development and commercialization of semiconductor devices and sensors related to quantum computing, medical diagnostics, TMR sensors, and lab-on-a-chip medical diagnostics in Australia. It offers qubit processor chip; and graphene-based lab-on-a-chip Biochip. The company was formerly known as Archer Exploration Limited and changed its name to Archer Materials Limited in October 2019. Archer Materials Limited was incorporated in 2007 and is based in Adelaide, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Archer Materials Limited reported revenue of $2.1M in FY2025 versus $468K in FY2021, a compound +44.8%/yr. Reported net income was −$7.0M in FY2025.
Is ARRXF fairly valued? → Check now
Similar stocks
10 more Semiconductors stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| NVIDIA Corporation NVDA | $205.10 | $115.06 | -44% |
| Taiwan Semiconductor Manufacturing Company TSMC34 | R$267.00 | R$181.37 | -32% |
| Broadcom Inc 1YD | €375.60 | €99.46 | -74% |
| Micron Technology, Inc ZMIC | C$52.57 | C$10.88 | -79% |
| SK hynix Inc 000660 | 1,000,000 KRW | 1,109,311 KRW | +11% |
| Advanced Micro Devices, Inc 1AMD | €464.70 | €56.33 | -88% |
| Intel Corporation INTC | C$68.40 | C$15.20 | -78% |
| Texas Instruments Incorporated TXN | $282.01 | $71.71 | -75% |
| QUALCOMM Incorporated QCOM | C$27.81 | C$21.04 | -24% |
| MediaTek Inc 2454 | 4,300 TWD | 1,081 TWD | -75% |
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is Archer Materials Limited (ARRXF) undervalued?
What is the fair value of ARRXF?
What is the quality score of ARRXF?
What is the revenue of Archer Materials Limited (ARRXF)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Archer Materials Limited analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.